SMS Pharmaceuticals Wins Tax Appeal, Vacating Rs 45.63 Crore Liability

Demand of Rs 45.63 crore cancelled by tax authorities.
Appellate order dated October 30, 2026, overturns 2025 assessment demand.

Reader Takeaway: The company gains significant balance sheet relief as a major tax liability is officially reversed by authorities.

What just happened

SMS Pharmaceuticals Limited has successfully challenged an income tax assessment for the 2023-24 assessment year. The Commissioner of Income-tax (Appeals) at the National Faceless Appeal Centre, Delhi, issued an order on October 30, 2026, that ruled in favor of the company. This order effectively vacates a tax demand, including interest, totaling Rs 45.63 crore, which was initially imposed by the Assessment Unit in March 2025.

Why this matters

For investors, this outcome is a material positive event. The removal of this liability means the company is no longer required to make provisions for or pay the disputed sum. It eliminates a contingent financial risk that had been highlighted in the company's previous regulatory disclosures, providing clarity and strengthening the company's cash position.

The backstory

On March 24, 2025, SMS Pharmaceuticals informed the stock exchanges that it had received an assessment order under Section 144 of the Income Tax Act, 1961, demanding Rs 45.63 crore. The company promptly contested this order by filing an appeal with the Commissioner of Income-tax (Appeals). The successful resolution of this appeal confirms the reversal of the tax demand.

What to track next

Shareholders should monitor the company's upcoming quarterly financial statements to observe the reversal of any associated provisions or debt-related interest charges previously accounted for in relation to this tax dispute.